

Express Mail Label No.: EV1395023US
Date of Deposit: July 29, 2002

07-30-02

Attorney Docket No: 21578-013RCE

RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS :Nathan H. Sloane

SERIAL NUMBER :08/986,606

EXAMINER :A Davenport

FILING DATE :December 8, 1997

ART UNIT :1653

FOR :SIXTEEN AMINO ACID OF THE ANTOINEOPLASTIC PROTEIN (ANUP)
AS A PHARMACOLOGICALLY ACTIVE ANTI-TUMOR AGENT

July 29, 2002

Boston, Massachusetts

RECEIVED

Commissioner of Patents
Washington, D.C. 20231

AUG 05 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

- Amendment in Response (12 pgs.);
- Copy of Notice of Improper Request for Continued Examination (1 pg.);
- Change of Attorney Docket Number; and
- Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21578-013RCE. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,

Ingrid Beattie

Ingrid Beattie 42,306
Attorney for Applicants
c/o MINTZ LEVIN COHN FERRIS
GLOVSKY & POPEO, PC
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542 6000
Fax: (617) 542-2241



30623

PATENT TRADEMARK OFFICE



Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

APPLICATION NUMBER FILING DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO/TITLE

RECEIVED

AUG 05 2002

TECH CENTER 1600/2900

DATE MAILED:



NOTICE OF IMPROPER REQUEST FOR CONTINUED EXAMINATION (RCE)

The request for continued examination (RCE) under 37 CFR 1.114 filed on
06/19/02 is improper for reason(s) indicated below:

- 1. Continued examination under 37 CFR 1.114 does not apply to an application for a design patent. Applicant may wish to consider filing a continuing application under 37 CFR 1.53(b) or a CPA under 37 CFR 1.53(d).
- 2. Continued examination under 37 CFR 1.114 does not apply to an application that was filed before June 8, 1995. Applicant may wish to consider filing a continuing application under 37 CFR 1.53(b) or a CPA under 37 CFR 1.53(d).
- 3. Continued examination under 37 CFR 1.114 does not apply to an application unless prosecution in the application is closed. If the RCE was accompanied by a reply to a non-final Office action, the reply will be entered and considered under 37 CFR 1.111. If the RCE was not accompanied by a reply, the time period set forth in the last Office action continues to run from the mailing date of that action.
- 4. The request was not filed before payment of the issue fee, and no petition under 37 CFR 1.313 was granted. If this application has not yet issued as a patent, applicant may wish to consider filing either a petition under 37 CFR 1.313 to withdraw this application from issue, or a continuing application under 37 CFR 1.53(b).
- 5. The request was not filed before abandonment of the application. The application was abandoned, or proceedings terminated on _____. Applicant may wish to consider filing a petition under 37 CFR 1.137 to revive this abandoned application.
- 6. The request was not accompanied by the fee set forth in 37 CFR 1.17(e) as required by 37 CFR 1.114. Since the application is not under appeal, the time period set forth in the final Office action or notice of allowance continues to run from the mailing date of that action or notice.
- 7. The request was not accompanied by a submission as required by 37 CFR 1.114. Since the application is not under appeal, the time period set forth in the final Office action or notice of allowance continues to run from the mailing date of that action or notice.

Note: If a request for a continued prosecution application (CPA) under 37 CFR 1.53(d) has been filed in the utility or plant application (including a previously filed CPA) that was filed on or after May 29, 2000, the request for a CPA has been treated as a RCE because the CPA practice no longer applies to such application. The constructive RCE, however, is improper for reason(s) indicated above.


A copy of this notice MUST be returned with any reply.

Direct the reply and any questions about this notice to:

Daveina B. Williams _____ Examining Group 1600/Art Unit 1653
(703) 306-4087.

Express Mail Label No.: EV139502068US

Date of Deposit: July 29, 2002



Attorney Docket No: 21578-013RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Sloane, Nathan H.

SERIAL NUMBER : 08/986,606

EXAMINER: R. Teller

FILING DATE : December 8, 1997

ART UNIT: 1653

FOR : Sixteen Amino Acid of the Antineoplastic Protein (ANUP) as a
Pharmacologically Active Anti-Tumor Agent

Box Sequence


Commissioner for Patents
Washington, DC 20231

**STATEMENT IN SUPPORT OF COMPUTER READABLE
FORM SUBMISSION UNDER 37 C.F.R. § 1.821(f)**

I hereby state that the content of the paper and computer readable forms of the Sequence Listing, submitted in the above-identified application in accordance with 37 C.F.R. § 1.821(c) and 1.821(e), respectively, are the same. No new matter is added at this time.

Respectfully submitted,

Dated: July 29, 2002



Sean M. Coughlin 48,593
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1678872v1

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

Express Mail Label No.: EV13950288US
Date of Deposit: July 29, 2002



Attorney Docket No: 21578-013RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Sloane, Nathan H.
SERIAL NUMBER : 08/986,606 EXAMINER: R. Teller
FILING DATE : December 8, 1997 ART UNIT: 1653
FOR : Sixteen Amino Acid of the Antineoplastic Protein (ANUP) as a Pharmacologically Active Anti-Tumor Agent

Box Sequence
Commissioner for Patents
Washington, DC 20231

RECEIVED
AUG 05 2002
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the present application are the following documents:

- Preliminary Amendment (1 pg.);
- Paper Copy of the Sequence Listing (1 pg.);
- Computer Readable Form Copy of the Sequence Listing (1 diskette);
- Statement in Support of Computer Readable Form Submission (1 page); and
- Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21578-013RCE. A duplicate copy of this Transmittal Letter is enclosed.

Respectfully submitted,


Ingrid Beattie 42,306
Attorney for Applicants
c/o MINTZ LEVIN COHN FERRIS
GLOVSKY & POPEO, PC
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542 6000
Fax: (617) 542-2241



30623

PATENT TRADEMARK OFFICE